Combining carefully selected drug, patient genetics may lead to total tumor death.
R. Tuma
DOI: https://doi.org/10.1093/JNCI/DJM194
2007-10-17
Journal of the National Cancer Institute
Abstract:D rug combinations carefully designed to maximize the agents’ effects are nothing new in cancer care. But researchers developing a new targeted therapy are taking the approach one step farther. Instead of combining it with another drug, they are following geneticists and relying on existing mutations in the cancer cells to give the drug its extra power. They are using a small-molecule inhibitor that blocks one type of DNA repair to fi ght tumors that already have mutations in another DNA repair pathway. Although neither the drug nor the mutation alone is enough to kill tumor cells, inhibiting two DNA repair systems ap pears to be lethal. With early clinical data hinting that the approach will work, a select group of international researchers are testing the idea in ovarian and breast cancer patients who carry mutations in the BRCA1 or BRCA2 gene. Many companies have taken note and aim to capitalize on the drug – mutation combination — called a synthetic lethal approach — in one manner or another. The drugs generating the buzz inhibit poly(ADP-ribose) polymerase (PARP). PARP detects single-strand breaks in DNA and is required for their repair in a pathway called base excision repair. Because many chemotherapy drugs are DNA-damaging agents, the inhibitors could help commonly used anticancer drugs work better when used in combination therapy. The synthetic lethal approach is likely to be even more powerful, however. “What excites us is the whole synthetic lethal approach,” said Vincent Giranda, M.D., Ph.D. , a project leader in cancer research at Abbott in Abbott Park, Ill. “That hasn’t been very successful over the years, where zero plus zero equals something. But (for) cancer — where DNA repair is often compromised — the base excision repair pathway, of which PARP is an essential part, is conserved.” That conservation suggests that tumor cells rely heavily on the base excision repair pathway — and that blocking it could be a serious problem for tumors, especially if another DNA repair pathway is already compromised by a mutation. Abbott is one of the companies developing a PARP inhibitor. Preclinical data support the synthetic lethal approach. Alan Ashworth, Ph.D., and colleagues at the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London, have reported that tumor cells that lack either the BRCA1 or BRCA2 gene, which is required for repair of double-strand DNA breaks, are especially sensitive to PARP inhibition. Wild-type cells and those with one functional copy of a BRCA gene and one mutant copy could grow in the presence of a PARP inhibitor. By contrast, cells that were defi cient in either BRCA1 or -2 rapidly stopped growing, showed chromosome instability, and underwent apoptosis, or programmed cell death. The team saw similar results when they tested cells in vitro and in animal models. Because the drug is not toxic to wild-type and BRCA heterozygous cells, it could be useful in selectively killing tumor cells, with few toxic effects. Following up on those laboratory data, AstraZeneca sponsored a phase I trial with its PARP inhibitor, AZD2281 (previously KU-59436). Early results, presented at the annual meeting of the American Society for Clinical Oncology in June, showed that the agent was relatively well tolerated, with some rare, reversible side effects (low mood and grade 4 reduction in platelet cells) and more common, but less severe, nausea and fatigue. The data also hint that the drug alone has some activity in patients with he reditary ovarian cancer, whose tumors are defi cient in BRCA1 or -2 (six of 11 patients showed some response). Few breast cancer patients are enrolled in the phase I study, so the drug’s potential activity for those patients is still unknown. “As a concept, there are a number of hypothetical areas where you could combine loss of one pathway and block off another and get an enhanced effect. But I think this is certainly one of the fi rst, if not the fi rst, experiments aimed at trying to show that effect and succeeding in a clinical trial,” said James Carmichael, M.D., chief medical offi cer at KuDOS Pharmaceuticals in Cambridge, UK, which originally developed AZD2281.